KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMY) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to 18.34%.

  • Bristol Myers Squibb's EBITDA Margin rose 82600.0% to 18.34% in Q3 2025 from the same period last year, while for Sep 2025 it was 12.48%, marking a year-over-year increase of 281700.0%. This contributed to the annual value of 17.89% for FY2024, which is 351300.0% down from last year.
  • As of Q3 2025, Bristol Myers Squibb's EBITDA Margin stood at 18.34%, which was up 82600.0% from 9.63% recorded in Q2 2025.
  • Bristol Myers Squibb's EBITDA Margin's 5-year high stood at 21.09% during Q4 2021, with a 5-year trough of 99.16% in Q1 2024.
  • Moreover, its 5-year median value for EBITDA Margin was 13.95% (2022), whereas its average is 8.64%.
  • Per our database at Business Quant, Bristol Myers Squibb's EBITDA Margin soared by 1418100bps in 2021 and then crashed by -1183400bps in 2024.
  • Quarter analysis of 5 years shows Bristol Myers Squibb's EBITDA Margin stood at 21.09% in 2021, then tumbled by -34bps to 13.87% in 2022, then fell by -6bps to 13.09% in 2023, then tumbled by -81bps to 2.45% in 2024, then skyrocketed by 650bps to 18.34% in 2025.
  • Its last three reported values are 18.34% in Q3 2025, 9.63% for Q2 2025, and 20.27% during Q1 2025.